Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2016
Subretinal Hemorrhage Due to SRNVM, Fluorescein Angiogram Photograph
James B. Soque, CRA, OCT-C, COA, FOPS
Pamela Ann Weber, MD
Retina Image Bank: Images of the Week
2016
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Updates from the Field
2021

Category: AMD-Neovascular

See more